Many challenges are encountered within Existing Biopharmaceutical Production Systems. For example, optimization for antibody production but often the yields for complex proteins are very low. There is also a lack of correct post-translational modifications, limited to non-human/ immunogenic post translational modifications. The different production systems and therefore protein qualities, also present a challenge. What other challenges face vaccine production? Tell us below!
Dr Hartmut Tintrup, Director Marketing & Business Development from CEVEC joined us at the World Vaccine Cell Culture Congress 2012 in Washington to discuss the development of CAP Cells: a human suspension cell line derived from primary amniocytes. The CAP cell line offers significant advantages: stables and high expression of human proteins, human-like post-translational modifications, growth in suspension, high cell density, non-tumour origin, easy accessibility, fast cell line development, stable growth parameters, all of which means that this technology is well suited for vaccine production. Dr Tintrup further details the capabilities of this technology through the discussion of the case study: Influenza virus production in CAP cells.
Why not download the full presentation and discover more about Influenza virus production in an amniocyte-derived human cell line:
- Advantages of serum-free suspension cells versus egg-based production technologies
- Exploring the potential of CEVEC's amniocyte production (CAP) cells for high-titer influenza virus production
- Strategies for process optimization in order to further simplify manufacturing and increase titers